DNA Q4 2022 Earnings — Ginkgo Bioworks Holdings, Inc. Revenue & Financial Results | Market Cap Arena

DNAGinkgo Bioworks Holdings, Inc.

$418M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$98M-33.8% YoY

Gross Profit

$68M69.3% margin

Operating Income

-$235M-238.6% margin

Net Income

-$177M-179.6% margin

EPS (Diluted)

$-3.85

QoQ Revenue Growth

+48.0%

Cash Flow

Operating Cash Flow

-$105M

Free Cash Flow

-$130M

Stock-Based Comp.

$118M

Balance Sheet

Total Assets

$2.5B

Total Liabilities

$803M

Stockholders' Equity

$1.7B

Cash & Equivalents

$1.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$98M	$148M	-33.8%
Gross Profit	$68M	$82M	-16.9%
Operating Income	-$235M	-$1.7B	+86.1%
Net Income	-$177M	-$1.6B	+89.0%

Revenue Segments

Foundry Revenue

$53M54%

Service

$33M33%

Product

$12M13%